Hyperlipidemia

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Retrieved on: 
Friday, March 22, 2024
Nephrotoxicity, Urinary tract infection, Fungal infection, Culture, Ventilator-associated pneumonia, Burns, Internal medicine, Amphotericin B, Emphysema, Azole, Coronary artery disease, Debridement, Carcinoma, Risk, Hyperlipidemia, Patient, Lung, LNC, Fusarium, Female, Malignancy, University, Doctor of Philosophy, MD, Aspergillosis, Echinocandin, Fever, Immune system, Division, Hypertension, Voriconazole, Physician, Infection, Pharmaceutical industry

The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.

Key Points: 
  • The successful MAT2203 treatment outcome in these patients therefore adds to our confidence for the upcoming ORALTO Phase 3 trial in patients suffering from invasive aspergillosis with limited treatment options.
  • She was transitioned to oral MAT2203 for two weeks, which led to clinical resolution of her fungal infection.
  • She began to show clinical improvement following two weeks of oral MAT2203 treatment and her skin wounds completely healed following six months of MAT2203 treatment.
  • “MAT2203 continues to demonstrate its potential to effectively treat invasive fungal infections and help patients achieve complete clinical resolution.

Innovating "Treadmill Exercise Test AI-Assisted Interpretation System," CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Retrieved on: 
Tuesday, April 2, 2024
Depression, Thrombosis, Myocardial infarction, Sudden death, Cardiovascular disease, Exercise, Survival, Coronary artery disease, ECG, Hyperlipidemia, Patient, Palpitations, Angina, Cancer, AI, Death, Moyamoya disease, Chronic pain, Plaque, Diet, Receiver, Smoking, Cardiac catheterization, Stenosis, Oxygen, Heart, Atherosclerosis, Rupture, Ministry, Duke, Vascular occlusion, CAD

To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.

Key Points: 
  • To address this issue, China Medical University Hospital (CMUH) AI Center successfully developed the "Treadmill Exercise Test AI-Assisted Interpretation System" which was trained with nearly a thousand treadmill ECG, in patients with coronary arterystenosisover 70% shown on their coronary angiography.
  • The program also utilizes ten measured features and two derived features including maximal work output and peak heart rate to determine the severity of coronary artery stenosis.
  • Generally, coronary heart disease in patients of middle or senior age is presented as angina or myocardial infarction and is one of the primary causes of sudden death."
  • Dr. Wu stated, "Coronary artery stenosis is a multi-factorial condition related to smoking, advanced age, diabetes hypertension and hyperlipidemia.

Molecular Templates, Inc. Provides Interim Update

Retrieved on: 
Monday, March 4, 2024
Therapy, Head, Neoplasm, Neck, CLS, AML, Part, TME, Sale, Pembrolizumab, Multiple myeloma, Bristol Myers Squibb, Symantec Endpoint Protection, TPS, Hyponatremia, Cytokine, Hypertension, Tumor microenvironment, Patient, Immunoglobulin A, MD Anderson Cancer Center, Hyperlipidemia, Disease, Biology, HNSCC, Hypercholesterolemia, CPS, PD-L1, Cancer, Pharmaceutical industry

Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.

Key Points: 
  • Unique pharmacodynamic effects demonstrating potent Treg clearance and IL-2 increases were observed at the first dose level.
  • MTEM intends to initiate a study of MT-0169 in CD38+ acute leukemias in collaboration with MD Anderson Cancer Center.
  • Additional details on each of these participant’s clinical profile and response to the investigational treatment are provided below.
  • MTEM plans on initiating an investigator sponsored trial with MD Anderson Cancer Center to evaluate MT-0169 in relapsed or refractory CD38+ AML patients.

Ruxoprubart (NM8074) Scores FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment

Retrieved on: 
Monday, February 12, 2024
LDH, Infection, FDA, Food, Hemoglobinuria, Paroxysmal nocturnal hemoglobinuria, Alternative complement pathway, ODD, Safety, Atypical hemolytic uremic syndrome, ANCA, Death, Patient, Hyperlipidemia, AP, Diagnosis, AAV, PNH, Chelsea Handler, Hemolysis, Pharmaceutical industry

FDA grants orphan drug designation to Ruxoprubart (NM8074) for the treatment of PNH.

Key Points: 
  • FDA grants orphan drug designation to Ruxoprubart (NM8074) for the treatment of PNH.
  • The FDA has approved phase 1b/Phase II clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G), Atypical Hemolytic Uremic Syndrome (aHUS), and most recently, ANCA vasculitis (AAV).
  • CLEVELAND, Feb. 12, 2024 (GLOBE NEWSWIRE) --  NovelMed today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).
  • FDA's recognition of Ruxoprubart as an orphan drug for PNH underscores its potential to fulfill a crucial need for individuals grappling with this disease condition.

Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award

Retrieved on: 
Tuesday, November 14, 2023
Health, Medical Devices, Diabetes, Neurology, Pharmaceutical, Cardiology, Biotechnology, Chronic kidney disease, Hypertension, Research, Therapy, PDT Standard, Better, Multimedia, Patient, FDA, Type 2 diabetes, Obesity, Neeraj, Hyperlipidemia, Frost, Pharmaceutical industry

(NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has been awarded Frost & Sullivan’s prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry.

Key Points: 
  • (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has been awarded Frost & Sullivan’s prestigious 2023 Best Practices Technology Innovation Leadership Award in the North American diabetes digital behavioral therapeutics industry.
  • View the full release here: https://www.businesswire.com/news/home/20231114156864/en/
    Better Therapeutics Receives 2023 Technology Innovation Award (Graphic: Business Wire)
    Frost & Sullivan's team of industry analysts conducted extensive research and in-depth interviews to evaluate multiple nominees before determining the final award recipient.
  • Furthermore, Better Therapeutics' proprietary platform offers the potential to rapidly expand its use to other cardiometabolic conditions in the future.
  • “A prominent factor that sets Better Therapeutics’ apart from competing solutions is its unique architecture that enables high scalability for the company to develop new prescription digital therapeutics.

Capital Rx and Vida Health Partner to Launch Rx Activate, a High-Touch Chronic Condition Management Program

Retrieved on: 
Tuesday, November 14, 2023
Mental, COPD, Hypertension, Heart, Depression, Social isolation, Doctor of Pharmacy, Patient, Health, Anxiety, PBA, Hyperlipidemia, Diabetes, Prediabetes, Asthma, PBM, Food, Cryptocurrency, Pharmaceutical industry, Nursing

Rx Activate combines Capital Rx's JUDI® with Vida's solutions to address some of the most prevalent chronic conditions.

Key Points: 
  • Rx Activate combines Capital Rx's JUDI® with Vida's solutions to address some of the most prevalent chronic conditions.
  • With chronic conditions driving over $3.6 trillion in total healthcare expenditures in the U.S., it's hard to ignore the problem plan sponsors face.
  • Capital Rx and Vida are addressing some fundamental gaps in care with a formulary- and benefit-aligned program: Rx Activate includes high-touch medication management supported by exceptional member service to build trust with providers and patients and help bring down the total cost of care.
  • Together, JUDI and Vida's digital tools can offer chronic condition management and high-touch cardiometabolic care that delivers equitable health outcomes, addressing members regardless of socioeconomic status.

Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion

Retrieved on: 
Tuesday, October 24, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Documentation, United Kingdom, MRI, DSM-IV codes, Medication, Hyperlipidemia, NCT, Mortality, Endocrinology, Diabetes, Disease, Osteopenia, Hyperglycemia, Adrenal tumor, Hypertension, ACS, CT, Syndrome, Safety, Patient, Death, Cardiovascular disease, Rheumatology, Pharmaceutical industry, Sparrow

This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.

Key Points: 
  • This trial will complement the ongoing Phase 2 RESCUE study (NCT number: NCT05307328 ) for the treatment of ACTH-dependent Cushing’s syndrome.
  • The study will examine SPI-62's effect on morbidities of hypercortisolism including diabetes or impaired glucose tolerance, hyperlipidemia, hypertension, and osteopenia.
  • Sparrow is actively enrolling up to 30 participants in ACSpire at sites in the United States, soon to be joined by sites in Romania, France, and the United Kingdom.
  • To learn more about Sparrow Pharmaceuticals and its clinical trials, visit the website at www.sparrowpharma.com .

9amHealth Expands Into Health Plans Through Collaboration With Women-Led Medicare Advantage Plan, EternalHealth

Retrieved on: 
Thursday, October 19, 2023
Hyperlipidemia, Physician, SAN, Nutritionist, Obesity, Medicine, Diabetes, Pharmacist, Hypertension, Partnership, Pharmacy, Health, West Midlands CARE Team, Medicare, Health insurance, Pharmaceutical industry, Health care, Nursing

SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- 9amHealth, the first-of-its-kind virtual cardiometabolic care clinic, is proud to announce its expansion into the health plan sector with a forward-looking partnership with Medicare Advantage plan, eternalHealth. This venture marks a significant milestone for 9amHealth as it brings its innovative and comprehensive care approach to the Medicare Advantage sector for the first time.

Key Points: 
  • SAN DIEGO, Oct. 19, 2023 /PRNewswire/ -- 9amHealth , the first-of-its-kind virtual cardiometabolic care clinic, is proud to announce its expansion into the health plan sector with a forward-looking partnership with Medicare Advantage plan, eternalHealth.
  • This venture marks a significant milestone for 9amHealth as it brings its innovative and comprehensive care approach to the Medicare Advantage sector for the first time.
  • "We believe virtual care should play a central role in improving the lives of Medicare Advantage plan members," says Christi Baker, Director of Medical Management at eternalHealth.
  • eternalHealth has chosen 9amHealth as a partner to offer a differentiated experience for our members in a crowded market."

Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances

Retrieved on: 
Thursday, October 5, 2023
Cardiology, Data Management, Technology, FDA, Other Health, Diabetes, Health, Health Technology, Apps, Applications, Software, Clinical Trials, Cognitive behavioral therapy, Biomarker, Diet, Hypertension, Obesity, Translation, Public, Prevalence, AGA, T2D, MD, Liver disease, Therapy, Smartphone, Safety, NASH, Principal, Senior counsel, PDT, Elastography, American Gastroenterological Association, NAFLD, ALT, CBT, Hyperlipidemia, MASH, Enzyme, Patient, Quality of life, Dietary supplement, Pharmaceutical industry, Medical imaging

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the pre-print publication of the LivVita study's results in Gastro Hep Advances, a peer reviewed journal produced by the American Gastroenterological Association (AGA).

Key Points: 
  • Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced the pre-print publication of the LivVita study's results in Gastro Hep Advances, a peer reviewed journal produced by the American Gastroenterological Association (AGA).
  • The study successfully met its primary endpoint by reducing liver fat within 90 days, while also achieving key secondary endpoints related to improved liver health without any device related adverse events.
  • The LivVita study evaluated Better Therapeutics’ novel CBT platform that targets individuals’ thoughts and beliefs related to improving healthy behaviors, such as diet and physical activity.
  • Better Therapeutics' novel CBT platform has already demonstrated clinically meaningful outcomes in type 2 diabetes (T2D), hypertension, and hyperlipidemia.

Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023

Retrieved on: 
Wednesday, October 11, 2023
Weight gain, Hepatology, Central nervous system, Mouse, AASLD, Psilocybin, Hyperglycemia, CORAL, American Association for the Study of Liver Diseases, Therapy, Liver, Hyperlipidemia, CNS, Dietary supplement

The data demonstrate the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD).

Key Points: 
  • The data demonstrate the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD).
  • Relmada intends to enter human studies of its proprietary, non-psychedelic/low dose modified-release formulation of psilocybin for metabolic indications.
  • "There are currently no approved drugs for MASLD, and these initial pre-clinical results support the therapeutic potential of non-psychedelic/low dose psilocybin.
  • Abstract Number: 2468-C, THE SEROTONIN RECEPTOR AGONIST PSILOCYBIN AS A NOVEL THERAPEUTIC APPROACH FOR NAFLD: PRECLINICAL STUDIES.